11/15/2023 0 Comments Merck millipore sigma aldrich![]() They’d get their order probably five or ten days later. In the old days, scientists would order the compounds, equipment, and any materials they needed over the phone or through a catalog. Udit Batra: Researchers’ expectations have also changed. The Quarterly: What other big changes are under way beyond technology? Imagine the amount of savings you could generate and how much you could speed up drug discovery and development if you were to substitute toxicology studies on animals with in vitro tests. Now, we have technologies where you can do screenings in in vitro settings with genetically modified cell lines that often mimic what’s happening in the human body-in many cases, better than rodent or primate models. Traditionally, discovery teams have spent roughly $300 million to $400 million on toxicology studies before a drug gets into early-stage clinical studies. ![]() Udit Batra: Technology is dramatically changing the way drugs are discovered and developed. The Quarterly: How has your industry been changing? The third part of our business is applied solutions, which is a mix of both segments. These range from bioreactor systems to chromatography equipment to filtration equipment to needles and filling equipment. We also offer what we call “process solutions”: the devices, systems, and compounds required in manufacturing environments to make and then purify small molecules and biologics that then become drugs. We sell filters, pipettes, high-grade research chemicals: essentially, all the products you’d need in a lab to conduct experiments. Udit Batra: We have a portfolio of more than 300,000 products that we market to researchers, regulated laboratories, and manufacturers. What products do you provide to customers? The Quarterly: Let’s start by helping readers understand MilliporeSigma’s business. In this conversation with McKinsey’s Roberta Fusaro, MilliporeSigma CEO Udit Batra describes the strategy that motivated the deal, the customer-centric focus that animated the integration process, and the ways in which he and his colleagues approached myriad operational, organizational, and cultural challenges. Vice chairman, Mass High Technology CouncilĪdvisory-council member, University of Delaware and Princeton University departments of chemical engineering Head, global public health and market accessĬEO and country president, Australia and New Zealandīoard member, Greater Boston Chamber of Commerce and Massachusetts Biotechnology Council ![]() Holds a PhD in chemical engineering from Princeton University and a BS in chemical engineering from the University of Delaware Born January 7, 1971, in New Delhi, India ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |